Fosamax Osteonecrosis of the Jaw Settlement: Statute of Limitations for Fosamax in Arizona

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Drug Risks

For decades, general health and science information has served as the foundation for public understanding of medical risks and therapeutic benefits. This legacy context emphasized broad wellness principles, disease prevention, and the importance of informed patient decision-making. Within this framework, medications like bisphosphonates were introduced as interventions for bone density loss, with their benefits communicated through standard health education channels. As the volume of clinical data expanded, so did awareness of rare but serious adverse events associated with long-term medication use. Among these, the connection between bisphosphonate exposure and osteonecrosis of the jaw emerged as a significant concern, particularly in patients undergoing dental procedures or with pre-existing oral health conditions. This shift in focus from general health maintenance to specific drug-related risks represents a natural evolution in public health discourse. The transition becomes particularly relevant when considering occupational settings where individuals may face prolonged or heightened exposure to such medications, either through direct prescription or environmental factors. In mass production environments, workers handling pharmaceutical compounds or their precursors may encounter unique exposure pathways that differ from typical patient populations. This occupational dimension introduces additional variables—such as cumulative exposure duration, concurrent chemical interactions, and workplace safety protocols—that warrant careful consideration within the broader context of medication safety and public health.

Fosamax and Osteonecrosis of the Jaw: Medical Evidence

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Osteonecrosis of the jaw can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation often involves pain, swelling, infection, and exposed bone in the jaw. Diagnosis is based on clinical examination and imaging, with a history of bisphosphonate use being a key factor. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates inhibit osteoclast activity, reducing bone resorption and remodeling. In the jawbone, which has high turnover rates, this suppression can impair healing after dental procedures or microtrauma, leading to avascular necrosis. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular environment of the jaw that may predispose it to ONJ under bisphosphonate therapy.

Timeline, Warnings, and Risk Considerations

Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is a key risk consideration. The prescribing information for Fosamax includes a warning under section 5.4 specifically addressing osteonecrosis of the jaw, noting its association with bisphosphonate use and risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Similarly, the label for Fosamax Plus D includes the same warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings in informing patients and healthcare providers about the risk, particularly in the context of long-term use and dental procedures, may be subject to legal scrutiny. The limitations of use section notes that the optimal duration of use has not been determined, and for patients at low risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that prolonged exposure may increase risk, but the label does not explicitly quantify ONJ risk over time.

Statute of Limitations for Fosamax Claims in Arizona

For affected patients in Arizona, settlement-related considerations involve the statute of limitations for filing claims. In Arizona, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For Fosamax-related ONJ, this means the clock starts when the patient becomes aware of the jaw condition and its potential link to the medication. Given that ONJ can develop months after starting Fosamax and may be initially attributed to dental issues, the discovery date may be delayed. Patients should consult with legal counsel to determine their specific timeline. Settlement considerations also include the strength of evidence linking Fosamax to ONJ, the adequacy of warnings, and the severity of harm. The FDA label acknowledges the association, which may support claims, but the similar incidence in placebo groups in clinical trials could be a factor in defense arguments. In summary, Fosamax is associated with osteonecrosis of the jaw, a condition with known risk factors and a variable onset timeline. The prescribing information includes warnings, but the adequacy of these warnings is a matter of legal evaluation. For Arizona patients, the statute of limitations is a critical factor in pursuing settlement or litigation, and individualized legal advice is recommended.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Arizona?

In Arizona, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For Fosamax-related osteonecrosis of the jaw (ONJ), the clock starts when the patient becomes aware of the jaw condition and its potential link to the medication. Because ONJ can develop months after starting Fosamax and may initially be attributed to dental issues, the discovery date may be delayed. Patients should consult with legal counsel to determine their specific timeline.

What are the known risk factors for developing ONJ from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with duration of bisphosphonate exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.